Paris – Cellectis bioresearch, the specialist in Genome customization and subsidiary of Cellectis (Alternext: ALCLS), today announced that it has signed a non-exclusive agreement with Evrogen (Moscow, Russia) for access to its fluorescent proteins. This license allows Cellectis bioresearch to incorporate these proteins into its own products and will expand the company’s offering of Genome engineering tools.

Luc Selig, Sales and Marketing Director of Cellectis bioresearch, commented, “One of the key components of our kits is the integration matrix which enables the user to express a Gene of interest. By extending the choice of promoters and tags in these matrices, we can offer our clients a full range of methods to achieve single-phase developments, thus saving valuable time during experiments.”

Cellectis bioresearch develops and commercializes ready- and easy-to-use tools and technologies for the life science industry. These tools can be used to customize any cell for drug development, Protein production or functional genomics. To date, Cellectis bioresearch markets over one hundred products through its online store and international distribution network and sales forces.